Study of TP-3654 in Patients With Advanced Solid Tumors

Summary

TP-3654 is an oral PIM inhibitor. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with advanced solid tumors.

Timeline

Start

2019-04-16

Primary completion

2021-03-30

Completion

2021-07-08

Drugs

Indications